Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159750 · ClinicalTrials.gov registry record
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
A clinical trial of Migraine and Episodic Migraine, sponsored by Hospital Universitari Vall d'Hebron Research Institute.
- Recruiting
- Registry status
- 700
- Enrollment target
- 20
- Study locations
NCT07159750 is a study of Migraine and Episodic Migraine that is actively recruiting participants, run by Hospital Universitari Vall d'Hebron Research Institute. The registered enrollment target is 700 participants, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07159750, a study of Migraine and Episodic Migraine, is actively recruiting participants, sponsored by Hospital Universitari Vall d'Hebron Research Institute.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Conditions Studied
Interventions
- DRUG CGRP antibody or gepant
Study Locations (20)
Other
- FLENI - Buenos Aires
- Pontificia Universidad Católica de Chile - Santiago
- Neuromedica - Medellín
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno - Rovinj
- Charité Universitätsmedizin Berlin - Berlin
- LMU University Hospital - München
- University of L'Aquila - L’Aquila
- University of Modena and Reggio Emilia - Modena
- National Neurological Institute C. Mondino Foundation - Pavia
- IRCCS San Raffaele - Roma
- Neuroclinic Norway - Lillestrøm
- Wrocław Medical University - Wroclaw
- Hospital Santa Maria Lisbon - Lisbon
Barcelona
- Germans Trias i Pujol Hospital - Badalona
- Vall d'Hebron University Hospital - Barcelona
- Hospital Universitari de Bellvitge - L'Hospitalet de Llobregat
- Fundació Sanitària Mollet - Mollet del Vallès
- Hospital de Viladecans - Viladecans
Florida
- University of Miami, Miller School of Medicine - Miami
Selangor
- Universiti Putra Malaysia - Serdang
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07159750
The ClinicalTrials.gov registry entry for NCT07159750 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (99% higher). The listed sponsor is Hospital Universitari Vall d'Hebron Research Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which CGRP antibody or gepant is the first listed.
NCT07159750 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Barcelona, Florida.
Frequently Asked Questions
What is clinical trial NCT07159750 about?
NCT07159750 is a clinical study titled "Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine". The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, a...
What is the current status of trial NCT07159750?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2024-01-02. Estimated completion is 2026-01.
What conditions does trial NCT07159750 study?
This clinical trial studies the following conditions: Migraine, Episodic Migraine, Chronic Migraine, Headache.
What interventions are being tested in trial NCT07159750?
The interventions under investigation include: CGRP antibody or gepant (DRUG).
Who is sponsoring clinical trial NCT07159750?
This trial is sponsored by Hospital Universitari Vall d'Hebron Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159750 being conducted?
This trial has 20 study locations across Florida, Selangor, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.